124 related articles for article (PubMed ID: 27619981)
1. Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients.
Aaberg-Jessen C; Halle B; Jensen SS; Müller S; Rømer UM; Pedersen CB; Brünner N; Kristensen BW
J Neurooncol; 2016 Dec; 130(3):439-448. PubMed ID: 27619981
[TBL] [Abstract][Full Text] [Related]
2. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.
Aaberg-Jessen C; Christensen K; Offenberg H; Bartels A; Dreehsen T; Hansen S; Schrøder HD; Brünner N; Kristensen BW
J Neurooncol; 2009 Oct; 95(1):117-128. PubMed ID: 19430729
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients.
Lin Y; Wang JF; Gao GZ; Zhang GZ; Wang FL; Wang YJ
Chin Med J (Engl); 2013 Nov; 126(22):4295-300. PubMed ID: 24238516
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression.
Coulibaly B; Nanni I; Quilichini B; Gaudart J; Metellus P; Fina F; Boucard C; Chinot O; Ouafik L; Figarella-Branger D
Hum Pathol; 2010 Jun; 41(6):815-23. PubMed ID: 20303140
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
Aaberg-Jessen C; Sørensen MD; Matos ALSA; Moreira JM; Brünner N; Knudsen A; Kristensen BW
BMC Cancer; 2018 Mar; 18(1):270. PubMed ID: 29523123
[TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.
Aaberg-Jessen C; Fogh L; Sørensen MD; Halle B; Brünner N; Kristensen BW
Pathol Oncol Res; 2019 Jan; 25(1):59-69. PubMed ID: 28963609
[TBL] [Abstract][Full Text] [Related]
9. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
[TBL] [Abstract][Full Text] [Related]
10. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
11. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
12. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Kuvaja P; Würtz SØ; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
Cancer Biomark; 2007; 3(6):293-300. PubMed ID: 18048967
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
[TBL] [Abstract][Full Text] [Related]
14. [Increased expression of gelatinases A and B, matrilysin and TIMP-1 genes in human malignant gliomas ].
Nakano A; Tani E; Yamamoto Y; Furuyama J; Miyazaki K
Nihon Rinsho; 1995 Jul; 53(7):1816-21. PubMed ID: 7630025
[TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
17. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.
Kozłowski M; Laudański W; Mroczko B; Szmitkowski M; Milewski R; Łapuć G
Adv Med Sci; 2013; 58(2):227-34. PubMed ID: 23773968
[TBL] [Abstract][Full Text] [Related]
18. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
